Biomarker ID | 1359 |
PMID | 24682418 |
Year | 2014 |
Biomarker | NQO2 [SNP: rs10223369: C>T] |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Blood |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.80 (95% CI: 1.24–2.60) |
Effect on Pathways | Estradiol Pathway |
Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
Type of Biomarker | Prognostic |
Cohort | The genetic profiles of 526 men with organ-confined prostate cancer were examined |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.002 |
Method Used | MALDI-TOF |
Clinical | No |
Remarks | Cox regression models included PSA at diagnosis, Gleason score, pathologic T stage, age at diagnosis, neoadjuvant hormone therapy, smoking status, adjuvant therapy, surgical margin, and nodal invasion status. The major-allele homozygotes served as the reference group with a fixed HR of 1.00. |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |